Brief: Actinium Pharmaceuticals Announces Iomab-ACT Program Gene Therapy Collaboration With UC Davis
13/01/2020 12:53
Jan 13 (Reuters) - Actinium Pharmaceuticals Inc ATNM.A :
* ACTINIUM PHARMACEUTICALS ANNOUNCES IOMAB-ACT PROGRAM GENE
THERAPY COLLABORATION WITH UC DAVIS IN ONGOING CLINICAL TRIAL
FOR PATIENTS WITH HIV-RELATED LYMPHOMA
* ACTINIUM - TRIAL TO REPLACE CURRENT USED CHEMOTHERAPY
CONDITIONING WITH APAMISTAMAB-I-131, TO SELECTIVELY ELIMINATE
LYMPHOMA CANCER CELLS, STEM CELLS
Source text for Eikon: ID:nPnc8mv49a
Further company coverage: ATNM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities